114 related articles for article (PubMed ID: 8068726)
1. Studies on rat liver phosphatidate phosphohydrolase and plasma lipids: effect of HMG-CoA reductase inhibitors.
Humble E; al-Shurbaji A; Lund E; Berglund L
Biochim Biophys Acta; 1994 Aug; 1214(1):32-8. PubMed ID: 8068726
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of cholesterol synthesis and hepatic 3-hydroxy-3-methylglutaryl--CoA reductase in rats by simvastatin and pravastatin.
Del Puppo M; Rauli S; Galli Kienle M
Lipids; 1995 Nov; 30(11):1057-61. PubMed ID: 8569435
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens.
Kalinowski SS; Tanaka RD; Mosley ST
Exp Eye Res; 1991 Aug; 53(2):179-86. PubMed ID: 1915674
[TBL] [Abstract][Full Text] [Related]
5. Hepatic fatty acid metabolism as a determinant of plasma and liver triacylglycerol levels. Studies on tetradecylthioacetic and tetradecylthiopropionic acids.
Asiedu DK; al-Shurbaji A; Rustan AC; Björkhem I; Berglund L; Berge RK
Eur J Biochem; 1995 Feb; 227(3):715-22. PubMed ID: 7867630
[TBL] [Abstract][Full Text] [Related]
6. Effects of propionic acid and pravastatin on HMG-CoA reductase activity in relation to forestomach lesions in the rat.
Bueld JE; Bannenberg G; Netter KJ
Pharmacol Toxicol; 1996 Apr; 78(4):229-34. PubMed ID: 8861780
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Aoki T; Nishimura H; Nakagawa S; Kojima J; Suzuki H; Tamaki T; Wada Y; Yokoo N; Sato F; Kimata H; Kitahara M; Toyoda K; Sakashita M; Saito Y
Arzneimittelforschung; 1997 Aug; 47(8):904-9. PubMed ID: 9296275
[TBL] [Abstract][Full Text] [Related]
8. Effects of phenobarbital upon triacylglycerol metabolism in the rabbit.
Goldberg DM; Roomi MW; Yu A; Roncari DA
Biochem J; 1980 Oct; 192(1):165-75. PubMed ID: 7305894
[TBL] [Abstract][Full Text] [Related]
9. Relationship between translocation of long-chain acyl-CoA hydrolase, phosphatidate phosphohydrolase and CTP:phosphocholine cytidylyltransferase and the synthesis of triglycerides and phosphatidylcholine in rat liver.
Asiedu D; Skorve J; Demoz A; Willumsen N; Berge RK
Lipids; 1992 Apr; 27(4):241-7. PubMed ID: 1355578
[TBL] [Abstract][Full Text] [Related]
10. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Dansette PM; Jaoen M; Pons C
Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
[TBL] [Abstract][Full Text] [Related]
11. RG 12561 (dalvastatin): a novel synthetic inhibitor of HMG-CoA reductase and cholesterol-lowering agent.
Amin D; Gustafson SK; Weinacht JM; Cornell SA; Neuenschwander K; Kosmider B; Scotese AC; Regan JR; Perrone MH
Pharmacology; 1993; 46(1):13-22. PubMed ID: 8434028
[TBL] [Abstract][Full Text] [Related]
12. Induction of fatty acid synthesis by pravastatin sodium in rat liver and primary hepatocytes.
Fujioka T; Tsujita Y; Shimotsu H
Eur J Pharmacol; 1997 Jun; 328(2-3):235-9. PubMed ID: 9218706
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of triglyceride-lowering effect of an HMG-CoA reductase inhibitor in a hypertriglyceridemic animal model, the Zucker obese rat.
Kasim SE; LeBoeuf RC; Khilnani S; Tallapaka L; Dayananda D; Jen KL
J Lipid Res; 1992 Jan; 33(1):1-7. PubMed ID: 1552226
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
15. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats.
Johnston TP; Palmer WK
Pharmacotherapy; 1997; 17(2):342-7. PubMed ID: 9085326
[TBL] [Abstract][Full Text] [Related]
16. Increase in serum and bile cholesterol and HMG-CoA reductase by lovastatin in rats.
Yamauchi S; Linscheer WG; Beach DH
Am J Physiol; 1991 Apr; 260(4 Pt 1):G625-30. PubMed ID: 2018137
[TBL] [Abstract][Full Text] [Related]
17. Effect of hesperetin, a citrus flavonoid, on the liver triacylglycerol content and phosphatidate phosphohydrolase activity in orotic acid-fed rats.
Cha JY; Cho YS; Kim I; Anno T; Rahman SM; Yanagita T
Plant Foods Hum Nutr; 2001; 56(4):349-58. PubMed ID: 11678440
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not by pravastatin.
De Vries AC; Vermeer MA; Bredman JJ; Bär PR; Cohen LH
Exp Eye Res; 1993 Apr; 56(4):393-9. PubMed ID: 8500554
[TBL] [Abstract][Full Text] [Related]
19. Serum lipids, hepatic glycerolipid metabolism and peroxisomal fatty acid oxidation in rats fed omega-3 and omega-6 fatty acids.
Rustan AC; Christiansen EN; Drevon CA
Biochem J; 1992 Apr; 283 ( Pt 2)(Pt 2):333-9. PubMed ID: 1349473
[TBL] [Abstract][Full Text] [Related]
20. Association between hepatic triacylglycerol accumulation induced by administering orotic acid and enhanced phosphatidate phosphohydrolase activity in rats.
Cha JY; Mameda Y; Yamamoto K; Oogami K; Yanagita T
Biosci Biotechnol Biochem; 1998 Mar; 62(3):508-13. PubMed ID: 9571780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
